FDA Approves Keytruda® - Metastatic Breast Cancer Trial Talk

Special Topics

On November 13, 2020, the FDA approved pembrolizumab (Keytruda®)  in combination with chemotherapy for the treatment of patients with locally recurrent unresectable or metastatic triple-negative breast cancer (TNBC) whose tumors express PD-L1 as determined by an FDA approved test.

FDA grants accelerated approval to pembrolizumab for locally recurrent unresectable or metastatic triple negative breast cancer 

Last Modified on March 4, 2021

Tags:

SEARCH OUR SITE

for past articles or specific information.